- Home
- DTF vs ASRT Comparison
DTF vs ASRT Comparison
Compare DTF & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- ASRT
- Stock Information
- Founded
- DTF 1991
- ASRT 1995
- Country
- DTF United States
- ASRT United States
- Employees
- DTF N/A
- ASRT N/A
- Industry
- DTF Investment Managers
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- ASRT Health Care
- Exchange
- DTF Nasdaq
- ASRT Nasdaq
- Market Cap
- DTF 79.7M
- ASRT 79.1M
- IPO Year
- DTF N/A
- ASRT 1997
- Fundamental
- Price
- DTF $11.41
- ASRT $0.80
- Analyst Decision
- DTF
- ASRT Strong Buy
- Analyst Count
- DTF 0
- ASRT 1
- Target Price
- DTF N/A
- ASRT $3.00
- AVG Volume (30 Days)
- DTF 21.1K
- ASRT 223.5K
- Earning Date
- DTF 01-01-0001
- ASRT 11-10-2025
- Dividend Yield
- DTF 3.64%
- ASRT N/A
- EPS Growth
- DTF N/A
- ASRT N/A
- EPS
- DTF 0.44
- ASRT N/A
- Revenue
- DTF N/A
- ASRT $117,099,000.00
- Revenue This Year
- DTF N/A
- ASRT N/A
- Revenue Next Year
- DTF N/A
- ASRT $4.10
- P/E Ratio
- DTF $24.34
- ASRT N/A
- Revenue Growth
- DTF N/A
- ASRT N/A
- 52 Week Low
- DTF $10.29
- ASRT $0.51
- 52 Week High
- DTF $11.19
- ASRT $1.16
- Technical
- Relative Strength Index (RSI)
- DTF 52.93
- ASRT 38.83
- Support Level
- DTF $11.42
- ASRT $0.79
- Resistance Level
- DTF $11.44
- ASRT $0.88
- Average True Range (ATR)
- DTF 0.05
- ASRT 0.04
- MACD
- DTF -0.01
- ASRT -0.01
- Stochastic Oscillator
- DTF 55.00
- ASRT 10.35
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.